Neuroblastoma Clinical Trials in Washington D.C., District of Columbia

6 studies are recruiting for neuroblastoma in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

   This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuxima…

   Stage

   Phase 3

   Ages

   Up to 30

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   179 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06172296 on ClinicalTrials.gov

2. Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

   Background: - Laboratory investigators who are studying common childhood cancers are interested in developing a tissue repository to collect and store blood, serum, tissue, urine, or tumors of children who have cancer or adults who have common childhood cancers. To develop this repository, addition…

   Stage

   Not phased

   Ages

   0 and older

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   5 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT01109394 on ClinicalTrials.gov

3. Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

   This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lor…

   Stage

   Phase 3

   Ages

   1 to 30

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   164 in total

   Run by

   Children's Oncology Group

   See if you can join NCT03126916 on ClinicalTrials.gov

4. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

   This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may hel…

   Stage

   Phase 1

   Ages

   1 to 30

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   21 in total

   Run by

   Children's Oncology Group

   See if you can join NCT04851119 on ClinicalTrials.gov

5. Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

   This is a phase I dose-escalation study to determine the safety and feasibility of autologous CAR-TA T cells (B7-H3 CAR+ T cells administered with DNR-PRAME Tumor Antigen-specific T cells) following lymphodepleting chemotherapy in participants with relapsed/refractory rhabdomyosarcoma, Ewing sarcom…

   Stage

   Phase 1

   Ages

   1 to 23

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   Children's National Research Institute

   See if you can join NCT07172958 on ClinicalTrials.gov

6. A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

   This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have…

   Stage

   Phase 2

   Ages

   1 to 40

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   6 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05135975 on ClinicalTrials.gov